Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about NBIX, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Valbenazine FDA approved Apr 2017 · Ingrezza |
Schizophrenia | Phase 4 · NCT07105111 | Recruiting |
| Crinecerfont FDA approved Dec 2024 · Crenessity |
Congenital Adrenal Hyperplasia | Phase 3 · NCT04490915 | Active not recruiting |
| NBI-1117568 | Schizophrenia | Phase 3 · NCT06963034 | Recruiting |
| NBI-1065845 | Major Depressive Disorder | Phase 3 · NCT06786624 | Recruiting |
| Infacort | Adrenal Insufficiency | Phase 3 · NCT02733367 | Completed |
| Osavampator | Major Depressive Disorder | Phase 3 · NCT07196501 | Recruiting |
| Chronocort | Congenital Adrenal Hyperplasia | Phase 3 · NCT05063994 | Completed |
| Plenadren | Primary Adrenal Insufficiency | Phase 2 · NCT05222152 | Completed |
| NBIP-01435 | Congenital Adrenal Hyperplasia | Phase 2 · NCT07850739 | Not yet recruiting |
| NBI-921352 | SCN8A Developmental and Epileptic Encephalopathy Syndrome | Phase 2 · NCT05226780 | Terminated |
| NBI-827104 | Epileptic Encephalopathy | Phase 2 · NCT05301894 | Terminated |
| NBI-1117570 | Schizophrenia | Phase 2 · NCT07288333 | Recruiting |
| NBI-1117567 | Alzheimer's Disease | Phase 2 · NCT07832383 | Not yet recruiting |
| NBI-1070770 | Major Depressive Disorder | Phase 2 · NCT06267846 | Completed |
| NBI-1065890 | Tardive Dyskinesia | Phase 2 · NCT07365462 | Recruiting |
| NBIB-0000223 | Friedreich's Ataxia | Phase 1 · NCT07934303 | Not yet recruiting |
Also used in these trials (approved or third-party drugs, not NBIX's own candidates): Hydrocortisone, Therapeutic Hydrocortisone, Hydrocortisone modified release capsules, i.v. Hydrocortisone Injection, Hydrocortisone granules, Testosterone Undecanoate.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
NBIX holds $789.7M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NBIX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| JPMORGAN CHASE & CO. | Institution (13G, 5%+) | 5,300,390 | 5.24% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 5,257,941 | 5.19% | 2026-03-31 |
| Vanguard Portfolio Management | Institution (13G, 5%+) | 5,083,540 | 5.02% | 2026-09-30 |
| Kevin Charles Gorman Director · +5,248 options |
Insider | 517,797 | 0.51% | 2026-09-11 |
| Kyle Gano Chief Executive Officer, Director · +1,228 options |
Insider | 155,010 | 0.15% | 2026-11-01 |
| Eric Benevich Chief Commercial Officer |
Insider | 67,297 | 0.07% | 2026-09-11 |
| Darin Lippoldt Chief Legal Officer · +4,965 options |
Insider | 56,793 | 0.06% | 2026-09-11 |
| Eiry Roberts Chief Medical Officer · +9,820 options |
Insider | 51,331 | 0.05% | 2026-09-28 |
| Matt Abernethy Chief Financial Officer |
Insider | 42,808 | 0.04% | 2026-09-11 |
| Julie Cooke Chief Human Resources Officer |
Insider | 24,025 | 0.02% | 2026-09-11 |
| Jude Onyia Chief Scientific Officer · +13,268 options |
Insider | 22,647 | 0.02% | 2026-09-11 |
| Ingrid Delaet Chief Regulatory Officer · +7,478 options |
Insider | 18,289 | 0.02% | 2026-09-11 |
Share count 101,218,643 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NBIX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →